TWD72.7 -1.3 -1.8%
Last Trade - 5:30am
| Market Cap | £467.5m |
| Enterprise Value | £616.1m |
| Revenue | £276.2m |
| Position in Universe | 1357th / 6141 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2,310 | 5,522 | 5,903 | 6,424 | 6,429 | 9,175 | 10,697 | 11,870 | +31.8% | ||
| +337.1 | +717.7 | +31.1 | +18.8 | |||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | June 30, 1966 |
| Public Since | December 13, 2004 |
| No. of Shareholders: | 19,977 |
| No. of Employees: | 1,099 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Taiwan SE Weighted , |
| Exchange | Taiwan Stock Exchange |
| Shares in Issue | 245,353,964 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 17F,No 277 Songren Road Xinyi District, TAIPEI, 110, Taiwan |
| Web | http://www.lotuspharm.com.tw |
| Phone | +886 2 27005908 |
| Contact | Bjartur Shen (Deputy General Manager-Strategy & Finance) |
| Auditors | Deloitte & Touche LLP |
As of 5:30am, shares in Lotus Pharmaceutical Co are trading at TWD72.7, giving the company a market capitalisation of £467.5m. This share price information is delayed by 15 minutes.
Shares in Lotus Pharmaceutical Co are currently trading at TWD72.7 and the price has moved by -21.78% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Lotus Pharmaceutical Co price has moved by -40.64% over the past year.
Of the analysts with advisory recommendations for Lotus Pharmaceutical Co, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Lotus Pharmaceutical Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Lotus Pharmaceutical Co is scheduled to issue upcoming financial results on the following dates:
Lotus Pharmaceutical Co does not currently pay a dividend.
Lotus Pharmaceutical Co does not currently pay a dividend.
Lotus Pharmaceutical Co does not currently pay a dividend.
To buy shares in Lotus Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Lotus Pharmaceutical Co are currently trading at TWD72.7, giving the company a market capitalisation of £467.5m.
Here are the trading details for Lotus Pharmaceutical Co:
Based on an overall assessment of its quality, value and momentum, Lotus Pharmaceutical Co is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Lotus Pharmaceutical Co are currently priced at TWD72.7. At that level they are trading at 49.55% discount to the analyst consensus target price of 0.00.
Analysts covering Lotus Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of 4.517 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lotus Pharmaceutical Co. Over the past six months, the relative strength of its shares against the market has been -27.87%. At the current price of TWD72.7, shares in Lotus Pharmaceutical Co are trading at -7.61% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lotus Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 16.76. The shares are currently trading at TWD72.7.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lotus Pharmaceutical Co's management team is headed by:
Here are the top five shareholders of Lotus Pharmaceutical Co based on the size of their shareholding:
